DSM Makes Great Strides in Production Processes for Resvida Trans-Resveratrol

resVida trans-resveratrol has been chosen by internationally recognized research institutions that are currently conducting human clinical trials researching the effects of trans-resveratrol on cardiovascular health, aging and other health benefit areas.

10 Nov 2009 --- DSM Nutritional Products, the global leader in vitamins, carotenoids and functional health ingredients, announced that advances in manufacturing will allow the company to provide lower pricing, effective January 2010 for resVida brand of trans-resveratrol.

DSM cited significant progress in process efficiencies and technology optimization in the production of its resVida 99% pure trans-resveratrol. In addition, an increased number of resVida launches in the food, beverage and supplement markets has resulted in improved manufacturing economies of scale. Also contributing to this growth is the rising awareness of resveratrol among US adults.

"Recent data indicates a major increase in consumer awareness of resveratrol (up more than 4-fold over prior year to 23% (MultiSponsor Surveys, Oct 2008)), further indicating explosive growth potential," said Reto Rieder, Sr. Marketing Manager of DSM Nutritional Products, Inc.

DSM's resVida is the leading trans-resveratrol that has been self-affirmed GRAS by an independent panel of experts and is supported by a DSM’s comprehensive safety package, which has been recently published in Food and Chemical Toxicology 47 (2009) 2170–2182.

resVida trans-resveratrol has been chosen by internationally recognized research institutions that are currently conducting human clinical trials researching the effects of trans-resveratrol on cardiovascular health, aging and other health benefit areas. Positive results from the first human study demonstrating effects on cardiovascular health will be presented early December 2009 at the International Polyphenol and Health Conference in the UK.

"Initial trans-resveratrol offerings had the challenge of small scale production, limited sales and high production costs,” said Reto Rieder, “With improvements in DSM’s manufacturing processes and continuous increases in demand for resVida brand trans-resveratrol, we will be able to share the reduced costs with our customers."